Skip to main content

Table 2 PCR results associated with microscopy findings and clinical characteristics

From: Detection of remaining Plasmodium DNA and gametocytes during follow up after curative malaria treatment among returned travellers in Norway

Patient Species No. days since treatment Microscopy (parasite%) PCR Fever duration before treatment (days) Treatment Origin/years out of endemic area Comorbidity
No. 1 P.f + P.m 0 Pos (2) Pos 35 AL SSA/1 HIV
1 Pos (1) Posb,c     
No. 2 P.f 0 Pos (4) Pos 2 A, AL SSA/8 HIV
1 Pos (4) Posb,c     
No. 3 P.f 0 Pos (12)   3 A, AP Norway  
1 Neg Pos     
2 Neg Pos     
11 Neg Posb     
No. 4 P.f 0 Pos (< 1)a   38 AP SSA/10  
31 Neg Neg     
No. 5 P.f 0 Pos (< 1)   7 AL SSA/46  
32 Neg Pos     
No. 6 P.f 0 Pos (2) Pos 9 Q, A, AL SSA/21  
1 Pos (< 0.5) Posb,c     
37 Neg Pos     
No. 7 P.f 0 Pos (10) Pos 21 A, AL SSA/10 HIV
4 Neg Pos     
11 Neg Pos     
39 Neg Neg     
No. 8 P.f 0 Pos (30) Pos 3 A, Norway  
1 Pos (6) Posb,c   Erythrocyte   
45 Neg Pos   apheresis, AL   
No. 9 P.f 0 Pos (6)a   13 A, AP, AL SSA/17 Sickle cell disease
49 Neg Pos    
No.10 P.v 0 Pos (0.5)   10 AP, P SEA/30  
2 Posa Posb,c     
No. 11 P.v 0 Pos (0.5)a   Not known AP, P SSA  
6 Neg Pos    
No. 12 P.v 0 Pos Pos 2 A, AP, P Norway  
23 Neg Neg     
No. 13 P.v 0 Pos   6 C, P Norway  
54 Neg Neg     
  1. AL artemether-lumefantrine, A artesunate IV (intravenous), PA atovaquone-proguanil, Q quinine IV, C chloroquine, P primaquine, HIV human immunodeficiency virus, SSA sub-Saharan Africa, SEA Southeast Asia
  2. aGametocytes seen by microscopy
  3. bDetection of 18S mRNA transcripts (Produced by all parasite stages)
  4. cDetection of gametocyte-specific mRNA